tovorafenib
Jump to navigation
Jump to search
Indications
- patients >=6 months with relapsed or refractory pediatric low-grade glioma with a BRAF fusion, rearrangement, or BRAF V600 mutation
Contraindications
Dosage
- 400-600 mg orally, once weekly, with or without food (body surface area >= 0.9 m2)*[2]
- tablets 100 mg, oral suspension 25 mg/mL
* see[2] for dosing
Pharmacokinetics
Adverse effects
- hemorrhage
- phototoxicity
- hepatotoxicity
- growth retardation
- rash, fatigue, viral infection, nausea/vomiting, headache, pyrexia, dry skin, constipation, acne
- increased
- decreased
Drug interactions
- CYP2C8 inducers & inhibitors
Mechanism of action
- BRAF inhibitor
More general terms
References
- ↑ Food & Drug Administration FDA grants accelerated approval to tovorafenib for patients with relapsed or refractory BRAF-altered pediatric low-grade glioma. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-tovorafenib-patients-relapsed-or-refractory-braf-altered-pediatric
- ↑ 2.0 2.1 2.2 HIGHLIGHTS OF PRESCRIBING INFORMATION tovorafenib (Ojemda) tablets & oral suspension https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218033s000lbl.pdf